|
|
ACCURE UK: The feasibility of undertaking Appendicectomy to impact upon the Clinical Course of UlceRativE Colitis - The ACCURE-UK Trial Feasibility study
Speciality: IBD
Chief Investigator: Professor Thomas Pinkney
Funded By: RfPB Portfolio Study ID: 17515
Phase: Pilot/Feasibility
Initial Target Number of Patients: 48
|
|
|
ACCURE-UK 2: An international multicentre randomised controlled trial to assess the effect of Appendectomy on the Clinical Course of UlceRativE colitis; UK Arm
Speciality: IBD
Chief Investigator: Professor Thomas Pinkney
Funded By: EME Portfolio Study ID: 40580
Phase: Phase III
Initial Target Number of Patients: 90
|
|
|
AceticA: A clinical trial looking at the efficacy and optimal dose of acetic acid in burn wound infections
Speciality: Burns
Chief Investigator: Mr Naiem Moiemen
Funded By: SRMRC Portfolio Study ID: 36451
Phase: Phase II
Initial Target Number of Patients: 20
|
 |
ADaPT: Androgen precursor Dehydroepiandrosterone Pharmacokinetics in Trauma
Speciality: Trauma
Chief Investigator: Lt Col Mark Foster
Funded By: SRMRC Portfolio Study ID: N/A
Phase: Phase II
Initial Target Number of Patients: 270
|
|
|
AdUP: A trial looking at a biological therapy to treat prostate cancer that has come back after radiotherapy and hormone therapy
Speciality: Prostate Cancer
Chief Investigator: Mr Prashant Patel
Funded By: MRC/Department of Health Portfolio Study ID: 13599
Phase: Phase I
Initial Target Number of Patients: 15
|
|
|
BASIL-2: Multi-centre randomised controlled trial to compare the clinical and cost-effectiveness of a ‘vein bypass first’ with a ‘best endovascular treatment first’ revascularisation strategy for severe limb ischaemia due to infra-popliteal arterial disease
Speciality: Vascular
Chief Investigator: Professor Andrew Bradbury
Funded By: HTA Portfolio Study ID: 16699
Phase: Phase III
Initial Target Number of Patients: 600
|
|
|
BASIL-3: Multi-centre randomised controlled trial of clinical and cost-effectiveness of drug coated balloons, drug eluting stents and plain balloon angioplasty with bail-out bare metal stent revascularisation strategies for severe limb ischaemia due to femoro-popliteal disease
Speciality: Vascular
Chief Investigator: Professor Andrew Bradbury
Funded By: NIHR Portfolio Study ID: 19816
Phase: Phase III
Initial Target Number of Patients: 861
|
|
|
BIOMEDE: Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication
Speciality: Brain Chief Investigator: Prof Darren Hargrave
Funded By: CRUK Portfolio Study ID: N/A
Phase: Phase II
Initial Target Number of Patients: 80
|
 |
CHEETAH: Cluster randomised trial of sterile glove and instrument change at the time of wound closure to reduced surgical site infection. A trial of low and middle income countries (LMICs)
Speciality: General Surgery
Chief Investigator: Professor Dion Morton & Professor Peter Brocklehurst
Funded By: Global Surgery Portfolio Study ID: N/A
Phase: Phase III
Initial Target Number of Patients: 600 (pilot), 12,800 (main)
|
|
|
compARE: Phase III randomised controlled trial Comparing Alternative Regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer
Speciality: Head and Neck
Chief Investigator: Professor Hisham Mehanna
Funded By: CRUK Portfolio Study ID: 18621
Phase: Phase III
Initial Target Number of Patients: 650
|
|
|
CReST: The role of endoluminal stenting in the acute management of obstructing colorectal cancer
Speciality: Colorectal
Chief Investigator: Professor James Hill
Funded By: CRUK Portfolio Study ID: 4708
Phase: Phase III
Initial Target Number of Patients: 500
|
 |
CREST-2: ColoRectal Stenting Trial 2 - Uncovered vs covered endoluminal stenting in the acute management of obstructing colorectal cancer in the palliative setting.
Speciality: Colorectal
Chief Investigator: Professor James Hill
Funded By: NIHR HTA Portfolio Study ID: 32120
Phase: Phase III
Initial Target Number of Patients: 350
|
|
DESKTOP
III
|
DESKTOP III: A randomized multicenter study to compare the efficacy of additional tumor debulking surgery versus chemotherapy alone for recurrent platinum-sensitive ovarian cancer
Speciality: Ovarian Cancer
Chief Investigator: Professor David Luesley
Funded By: CTAAC Portfolio Study ID: 11498
Phase: Phase III
Initial Target Number of Patients: 100
|
 |
EAGLE: Safe-anastomosis Programme in Colorectal Surgery
Speciality: Colorectal Chief Investigator: Professor Dion Morton
Funded By: ESCP Portfolio Study ID: N/A
Phase: N/A Initial Target Number of Patients: 4400
|
|
|
ElaTION: The Efficacy and Cost effectiveness of Real Time Ultrasound Elastography in The Investigation Of Thyroid Nodules and the diagnosis of thyroid cancer
Speciality: Head and Neck
Chief Investigator: Professor Hisham Mehanna
Funded By: HTA Portfolio Study ID: 17373
Phase: Phase III
Initial Target Number of Patients: 1000
|
|
|
ENDCaP-C: Enhanced Neoplasia Detection and Cancer Prevention in Chronic Colitis: A Multicentre test accuracy study
Speciality: IBD
Chief Investigator: Professor Tariq Iqbal
Funded By: NIHR EME Portfolio Study ID: 17739
Phase: Phase III
Initial Target Number of Patients: 1000
|
|
|
EPIVIN: A trial of Veregen cream for women with vulval intraepithelial neoplasia
Speciality: Gynaecology Cancer
Chief Investigator: Professor David Luesley
Funded By: NIHR EME Portfolio Study ID: 15759
Phase: Phase II
Initial Target Number of Patients: 56
|
 |
FALCON: Pragmatic multicentre FActorial randomised controlled triaL testing measures to reduCe surgical site infection in lOw and middle income couNtries
Speciality: Colorectal
Chief Investigator: Professor Dion Morton
Funded By: Global Surgery Portfolio Study ID: N/A
Phase: Phase III
Initial Target Number of Patients: 5800
|
|
|
FEMME: A Randomised trial of treating Fibroids with either Embolisation or Myomectomy to Measure the Effect on quality of life, among women wishing to avoid hysterectomy: the FEMME study
Speciality: Reproductive Health
Chief Investigator: Professor Klim McPherson
Funded By: NIHR HTA Portfolio Study ID: 11877
Phase: Phase III
Initial Target Number of Patients: 224
|
|
|
FOxTROT: Fluoropyrimidine, Oxaliplatin and Targeted-Receptor pre-Operative Therapy for patients with high-risk, operable colon cancer
Speciality: Colorectal
Chief Investigator: Professor Dion Morton
Funded By: CRUK Portfolio Study ID: 3771
Phase: Phase III
Initial Target Number of Patients: 1050
|
|
|
IIH:WT: is a randomised controlled trial of bariatric surgery versus a community weight loss programme for the sustained treatment of Idiopathic Intracranial Hypertension
Speciality: Neurological
Chief Investigator: Dr Alexandra Sinclair
Funded By: NIHR Portfolio Study ID: 16025
Phase: Phase III
Initial Target Number of Patients: 60
|
|
|
NEO-EXCEL: Neoadjuvant trial of pre-operative exemestane or letrozole +/- celecoxib in the treatment of ER-positive postmenopausal early breast cancer
Speciality: Breast Cancer
Chief Investigator: Professor Daniel Rea
Funded By: CRUK Portfolio Study ID: 1729
Phase: Phase III
Initial Target Number of Patients: 256
|
 |
NOSTRA: Can patients with residual cancer after chemotherapy for early breast cancer be identified with multiple ultrasound-guided biopsies?
Speciality: Breast Cancer
Chief Investigator: Professor Daniel Rea
Funded By: CRUK / Roche Portfolio Study ID: 38071
Phase: Phase III
Initial Target Number of Patients: 150
|
|
|
LORIS: A trial comparing surgery with active monitoring for low risk DCIS
Speciality: Breast Cancer
Chief Investigator: Dr Matthew Wallis
Funded By: NIHR HTA Portfolio Study ID: 16736
Phase: Phase III
Initial Target Number of Patients: 932
|
|
|
ROCkeTS: Refining Ovarian Cancer Test Accuracy Scores: A test accuracy study to validate new risk scores in women with symptoms of suspected ovarian cancer
Speciality: Gynaecology
Chief Investigator: Mrs Sudha Sundar
Funded By: NIHR HTA Portfolio Study ID: 17994
Phase: Diagnostic Test Accuracy Trial
Initial Target Number of Patients: 2450
|
|
|
ROSCO: Response to Optimal Selection of neo-adjuvant Chemotherapy in Operable breast cancer: A randomised phase III, stratified biomarker trial of neoadjuvant 5-Fluorouracil, Epirubicin and Cyclophosphamide vs Docetaxel and Cyclophosphamide chemotherapy
Speciality: Breast Cancer
Chief Investigator: Professor Daniel Rea
Funded By: CRUK/Celgene Portfolio Study ID: 19069
Phase: Phase III
Initial Target Number of Patients: 1050
|
 |
ROSSINI 2: Reduction Of Surgical Site Infection using several Novel Interventions
Speciality: Colorectal
Chief Investigator: Professor Thomas Pinkney
Funded By: HTA Portfolio Study ID: 39722
Phase: Phase III
Initial Target Number of Patients: 6610
|
 |
SOCQER-2: Quality of Life Study in Patients Undergoing Surgery for Ovarian Cancer
Speciality: Gynaecology Cancer
Chief Investigator: Mrs Sudha Sundar
Funded By: NICE Portfolio Study ID: 19553
Initial Target Number of Patients: 120
|
 |
SMALL: Surgery versus Minimally invasive vacuum-Assisted excision for small screen-detected breast cancer – a phase III randomised multi-centre trial
Speciality: Breast Cancer
Chief Investigator: Mr Stuart McIntosh
Funded By: HTA Portfolio Study ID: 12240119
Phase: Phase III
Initial Target Number of Patients: 801
|
 |
STAR-TREC: Can we save the rectum by watchful waiting or transanal surgery following (chemo)radiotherapy versus total mesorectal excision for early rectal cancer?
Speciality: Colorectal
Chief Investigator: Mr Simon Bach
Funded By: CRUK Portfolio Study ID: 31203
Phase: Phase III
Initial Target Number of Patients: 120
|
 |
STOP-Colits Pilot Trial: A prospective, open-label, randomised pilot study to assess two possible routes of Faecal Microbiota Transplant (FMT) delivery in patients with ulcerative colitis.
Speciality: Gastroenterology
Chief Investigator: Professor Tariq Iqbal
Funded By: EME / NIHR Portfolio Study ID: 35522
Phase: Phase III (Pilot)
Initial Target Number of Patients: 30
|
 |
SUNRRISE: Single use negative pressure dressing for reduction in surgical site infection following emergency laparotomy
Speciality: IBD
Chief Investigator: Mr Richard Wilkin
Funded By: RfPB Portfolio Study ID: 36516
Phase: Phase III
Initial Target Number of Patients: 630
|
 |
TREC: Transanal Endoscopic Microsurgery (TEM) and Radiotherapy in Early Rectal Cancer
Speciality: Colorectal
Chief Investigator: Mr Simon Bach
Funded By: CRUK Portfolio Study ID: 7589
Phase: Phase III
Initial Target Number of Patients: 46
|
 |
WISTERIA: WEE1 Inhibitor With Cisplatin and Radiotherapy: A Trial in Head and Neck Cancer
Speciality: Head and Neck
Chief Investigator: Professor Hisham Mehanna
Funded By: NAC, ECMS/AZ Alliance Portfolio Study ID: 32918
Phase: Phase I
Initial Target Number of Patients: 42
|